GSTT1 null genotype increases risk of premenopausal breast cancer

Cancer Lett. 2002 Jul 8;181(1):73-9. doi: 10.1016/s0304-3835(02)00046-0.


The NAT2, GSTM1 and GSTT1 genes are known candidate cancer susceptibility markers and have been investigated in breast cancer susceptibility with conflicting results. We conducted a case-control study to investigate the role of NAT2, GSTM1 and GSTT1 in premenopausal breast cancer. Women with the GSTT1 null genotype were found to have a significant 3.15-fold increased risk of breast cancer (95% CI = 1.7-5.8), while GSTM1 and NAT2 genotypes were not associated with breast cancer risk. Our results suggest that the GSTT1 null genotype may play a role in early onset breast cancer.

MeSH terms

  • Adult
  • Arylamine N-Acetyltransferase / genetics
  • Arylamine N-Acetyltransferase / physiology
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / genetics*
  • Case-Control Studies
  • Female
  • Genotype
  • Glutathione Transferase / genetics*
  • Glutathione Transferase / physiology
  • Humans
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Premenopause / genetics*
  • Premenopause / metabolism*
  • Risk


  • Arylamine N-Acetyltransferase
  • NAT2 protein, human
  • glutathione S-transferase T1
  • Glutathione Transferase
  • glutathione S-transferase M1